Availability of substance use screening and treatment within HIV clinical sites across seven geographic regions within the IeDEA consortium.

Alcohol use Availability HIV Screening Substance use Treatment

Journal

The International journal on drug policy
ISSN: 1873-4758
Titre abrégé: Int J Drug Policy
Pays: Netherlands
ID NLM: 9014759

Informations de publication

Date de publication:
15 Jan 2024
Historique:
received: 16 08 2023
revised: 15 12 2023
accepted: 20 12 2023
medline: 16 1 2024
pubmed: 16 1 2024
entrez: 16 1 2024
Statut: aheadofprint

Résumé

Overwhelming evidence highlights the negative impact of substance use on HIV care and treatment outcomes. Yet, the extent to which alcohol use disorder (AUD) and other substance use disorders (SUD) services have been integrated within HIV clinical settings is limited. We describe AUD/SUD screening and treatment availability in HIV clinical sites participating in the International epidemiology Databases to Evaluate AIDS (IeDEA) consortium. In 2020, 223 IeDEA HIV clinical sites from 41 countries across seven geographic regions completed a survey on capacity and practices related to management of AUD/ SUD. Sites provided information on AUD and other SUD screening and treatment practices. Sites were from low-income countries (23%), lower-middle-income countries (38%), upper-middle income countries (17%) and high-income counties (23%). AUD and SUD screening using validated instruments were reported at 32% (n=71 located in 12 countries) and 12% (n=27 located in 6 countries) of the 223 sites from 41 countries, respectively. The North American region had the highest proportion of clinics that reported AUD screening (76%), followed by East Africa (46%); none of the sites in West or Central Africa reported AUD screening. 31% (n=69) reported both AUD screening and counseling, brief intervention, psychotherapy, or Screening, Brief Intervention, and Referral to Treatment; 8% (n=18) reported AUD screening and detox hospitalization; and 10% (n=24) reported both AUD screening and medication. While the proportion of clinics providing treatment for SUD was lower than those treating AUD, the prevalence estimates of treatment availability were similar. Availability of screening and treatment for AUD/SUD in HIV care settings is limited, leaving a substantial gap for integration into ongoing HIV care. A critical understanding is needed of the multilevel implementation factors or feasible implementation strategies for integrating screening and treatment of AUD/SUD into HIV care settings, particularly for resource-constrained regions.

Sections du résumé

BACKGROUND BACKGROUND
Overwhelming evidence highlights the negative impact of substance use on HIV care and treatment outcomes. Yet, the extent to which alcohol use disorder (AUD) and other substance use disorders (SUD) services have been integrated within HIV clinical settings is limited. We describe AUD/SUD screening and treatment availability in HIV clinical sites participating in the International epidemiology Databases to Evaluate AIDS (IeDEA) consortium.
METHODS METHODS
In 2020, 223 IeDEA HIV clinical sites from 41 countries across seven geographic regions completed a survey on capacity and practices related to management of AUD/ SUD. Sites provided information on AUD and other SUD screening and treatment practices.
RESULTS RESULTS
Sites were from low-income countries (23%), lower-middle-income countries (38%), upper-middle income countries (17%) and high-income counties (23%). AUD and SUD screening using validated instruments were reported at 32% (n=71 located in 12 countries) and 12% (n=27 located in 6 countries) of the 223 sites from 41 countries, respectively. The North American region had the highest proportion of clinics that reported AUD screening (76%), followed by East Africa (46%); none of the sites in West or Central Africa reported AUD screening. 31% (n=69) reported both AUD screening and counseling, brief intervention, psychotherapy, or Screening, Brief Intervention, and Referral to Treatment; 8% (n=18) reported AUD screening and detox hospitalization; and 10% (n=24) reported both AUD screening and medication. While the proportion of clinics providing treatment for SUD was lower than those treating AUD, the prevalence estimates of treatment availability were similar.
CONCLUSIONS CONCLUSIONS
Availability of screening and treatment for AUD/SUD in HIV care settings is limited, leaving a substantial gap for integration into ongoing HIV care. A critical understanding is needed of the multilevel implementation factors or feasible implementation strategies for integrating screening and treatment of AUD/SUD into HIV care settings, particularly for resource-constrained regions.

Identifiants

pubmed: 38228025
pii: S0955-3959(23)00356-0
doi: 10.1016/j.drugpo.2023.104309
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104309

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Kathryn E Lancaster (KE)

Wake Forest University School of Medicine, Winston-Salem, NC, USA. Electronic address: klancast@wakehealth.edu.

Melissa Stockton (M)

University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Molly Remch (M)

University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

C William Wester (CW)

Vanderbilt University Medical Center, Nashville, TN, USA.

Denis Nash (D)

City University of New York (CUNY), New York, NY, USA.

Ellen Brazier (E)

City University of New York (CUNY), New York, NY, USA.

Adebola Adedimeji (A)

Albert Einstein College of Medicine, Bronx, NY, USA.

Robert Finlayson (R)

Taylor Square Private Clinic, Syndey, Australia.

Aimee Freeman (A)

Johns Hopkins University, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Breanna Hogan (B)

Johns Hopkins University, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Charles Kasozi (C)

Masaka Regional Referral Hospital, Masaka City, Uganda.

Edith Kamaru Kwobah (EK)

Moi Teaching and Referral Hospital, Eldoret, Kenya.

Jayne Lewis Kulzer (JL)

University of California San Francisco (UCSF), San Francisco, CA, USA.

Tuti Merati (T)

Udayana University, Badung, Indonesia.

Judiacel Tine (J)

Centre Hospitalier National Universitaire de Fann, Dakar, Senagal.

Armel Poda (A)

Université Polytechnique de Bobo-Dioulasso, Bobo-Dioulasso, Burkina Faso.

Regina Succi (R)

Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.

Christelle Twizere (C)

Centre National de Référence en Matière de VIH/SIDA au Burundi, Bujumbura, Burundi.

Mpho Tlali (M)

University of Cape Town, Cape Town, South Africa.

Per von Groote (PV)

Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland.

E Jennifer Edelman (EJ)

Yale Schools of Medicine and Public Health, New Haven, CT, USA.

Angela M Parcesepe (AM)

University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Classifications MeSH